Biomedical Decision Intelligence for Biotech

We track and interpret evolving biomedical evidence to clarify uncertainty and its implications for therapeutic development, partnering, and portfolio decisions. Our initial focus is on rare diseases.

Discuss a Strategic Question

Read Strategic Insights

How It Works

1. Monitor

Track scientific, clinical, regulatory, and competitive developments over time to identify what has changed.

What We Do

2. Structure

Organize public evidence with traceable sources and the context needed to interpret it.

↓

↓

3. Analyze

Examine emerging patterns, evidence limitations, and unresolved questions.

↓

4. Inform

Clarify implications for therapeutic development, partnering, and portfolio decisions.

Capta Bio combines an internal AI-assisted intelligence system with founder-led analysis to interpret evolving biomedical evidence.

Our approach focuses on what has changed, why it matters, what uncertainty remains, and how new developments may influence strategic decisions. Our published Strategic Insights illustrate this approach across rare-disease therapeutic landscapes.

Rare Disease Intelligence

Structured monitoring and interpretation of therapeutic, clinical, and strategic developments.

Business Development Intelligence

Support opportunity assessment and partnership evaluation.

Competitive Intelligence

Track meaningful signals across emerging therapeutic landscapes.

Decision Support

Transform fragmented information into actionable strategic insights

  • Therapeutic Development Leaders

  • Business Development Teams

  • Corporate Strategy Leaders

  • Biotech Founders

  • Portfolio Decision Makers

Our work is relevant to biotech leaders evaluating therapeutic development, partnering, and portfolio decisions.

Who This Is For

Discuss a Strategic Question

What evidence could change your next development, partnering, or portfolio decision?

Share the therapeutic area and question you are considering. We can discuss whether a founder-led assessment would be useful.